Inotrem and the Crohn’s & Colitis Foundation sign a R&D collaboration agreement to support the development of a new therapeutic approach in Inflammatory Bowel Disease (IBD)
April 14, 2022
Paris (France), April 14th 2022. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D